EUR 0.64
(-6.16%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 46.49 Million EUR | 19.43% |
2022 | 38.93 Million EUR | -34.03% |
2021 | 59.01 Million EUR | -13.05% |
2020 | 67.87 Million EUR | 78.17% |
2019 | 38.09 Million EUR | 302.37% |
2018 | 9.46 Million EUR | -15.18% |
2017 | 11.16 Million EUR | -5.83% |
2016 | 11.85 Million EUR | -28.26% |
2015 | 16.51 Million EUR | 653.59% |
2014 | 2.19 Million EUR | 93.56% |
2013 | 1.13 Million EUR | 199.04% |
2012 | 378.71 Thousand EUR | 24.98% |
2011 | 303.01 Thousand EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 101.52 Million EUR | 0.0% |
2023 Q4 | 46.49 Million EUR | 0.0% |
2023 Q2 | 27.52 Million EUR | 0.0% |
2023 FY | 46.49 Million EUR | 19.43% |
2022 Q4 | 38.93 Million EUR | 0.0% |
2022 Q2 | 49.27 Million EUR | 0.0% |
2022 FY | 38.93 Million EUR | -34.03% |
2021 Q4 | 59.01 Million EUR | 0.0% |
2021 FY | 59.01 Million EUR | -13.05% |
2021 Q2 | 61.88 Million EUR | 0.0% |
2020 Q2 | 34.28 Million EUR | 0.0% |
2020 FY | 67.87 Million EUR | 78.17% |
2020 Q4 | 67.87 Million EUR | 0.0% |
2019 Q2 | 28.78 Million EUR | 0.0% |
2019 Q4 | 38.09 Million EUR | 0.0% |
2019 FY | 38.09 Million EUR | 302.37% |
2018 FY | 9.46 Million EUR | -15.18% |
2018 Q2 | 13.97 Million EUR | 0.0% |
2018 Q4 | 9.46 Million EUR | 0.0% |
2017 Q2 | 13.57 Million EUR | 0.0% |
2017 FY | 11.16 Million EUR | -5.83% |
2017 Q4 | 11.16 Million EUR | 0.0% |
2016 Q2 | 12.11 Million EUR | 0.0% |
2016 Q4 | 11.85 Million EUR | 0.0% |
2016 FY | 11.85 Million EUR | -28.26% |
2015 FY | 16.51 Million EUR | 653.59% |
2015 Q4 | 16.51 Million EUR | 0.0% |
2015 Q2 | 8.51 Million EUR | 0.0% |
2014 FY | 2.19 Million EUR | 93.56% |
2014 Q4 | 2.19 Million EUR | 0.0% |
2013 FY | 1.13 Million EUR | 199.04% |
2012 FY | 378.71 Thousand EUR | 24.98% |
2011 FY | 303.01 Thousand EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | -216.071% |
ABIVAX Société Anonyme | 327.06 Million EUR | 85.784% |
Adocia SA | 24.95 Million EUR | -86.304% |
Aelis Farma SA | 26.28 Million EUR | -76.911% |
Biophytis S.A. | 11.93 Million EUR | -289.528% |
Advicenne S.A. | 12.4 Million EUR | -274.741% |
genOway Société anonyme | 31.84 Million EUR | -46.013% |
IntegraGen SA | 8 Million EUR | -481.15% |
Medesis Pharma S.A. | 1.92 Million EUR | -2313.603% |
Neovacs S.A. | 47.53 Million EUR | 2.187% |
NFL Biosciences SA | 3.97 Million EUR | -1070.95% |
Plant Advanced Technologies SA | 14.91 Million EUR | -211.77% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -1140.911% |
Theranexus Société Anonyme | 7.23 Million EUR | -542.384% |
TME Pharma N.V. | 2.49 Million EUR | -1766.482% |
Valbiotis SA | 33.24 Million EUR | -39.84% |
TheraVet SA | 7.53 Million EUR | -517.108% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | -31.808% |
argenx SE | 4.11 Billion EUR | 98.869% |
BioSenic S.A. | 9.55 Million EUR | -386.391% |
Celyad Oncology SA | 16.28 Million EUR | -185.555% |
DBV Technologies S.A. | 165.65 Million USD | 71.932% |
Galapagos NV | 4.35 Billion EUR | 98.933% |
Genfit S.A. | 173.87 Million EUR | 73.26% |
GeNeuro SA | 6.31 Million EUR | -636.493% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 2.489% |
Innate Pharma S.A. | 184.19 Million EUR | 74.758% |
Inventiva S.A. | 69.13 Million EUR | 32.753% |
MaaT Pharma SA | 42.93 Million EUR | -8.3% |
MedinCell S.A. | 36.94 Million EUR | -25.837% |
Nanobiotix S.A. | 93.89 Million EUR | 50.484% |
Onward Medical N.V. | 43.62 Million EUR | -6.567% |
Oryzon Genomics S.A. | 106.9 Million EUR | 56.507% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 43.231% |
Oxurion NV | 6.55 Million EUR | -609.833% |
Pharming Group N.V. | 426.33 Million EUR | 89.095% |
Poxel S.A. | 4.82 Million EUR | -864.007% |
GenSight Biologics S.A. | 9.08 Million EUR | -411.655% |
Transgene SA | 45.21 Million EUR | -2.824% |
Financière de Tubize SA | 1.92 Billion EUR | 97.579% |
UCB SA | 15.53 Billion EUR | 99.701% |
Valneva SE | 469.39 Million EUR | 90.095% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | -50.813% |